{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-038301","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.891955+00:00","generated_at":"2026-05-23T07:26:40.292508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Merck reports Q1 2025 EPS $2.01, sales $15.5B; GARDASIL plunges 41% on China weakness","bullets":["GAAP EPS $2.01 (up 7% YoY); non-GAAP EPS $2.22 (up 7%); revenue $15.5B (-2% reported, +1% ex-FX).","KEYTRUDA sales $7.2B (+4% reported, +6% ex-FX); WINREVAIR $280M post-launch; Animal Health +5%.","GARDASIL sales fell 41% to $1.3B on lower China demand; ex-China sales grew 14% (16% ex-FX).","FY2025 non-GAAP EPS guidance revised to $8.82-8.97 from $8.88-9.03 due to $0.06 charge for Hengrui license.","Tariffs expected to add ~$200M cost in 2025; full-year sales outlook unchanged at $64.1B-$65.6B."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-038301","json":"https://secwatch.observer/filing/0001104659-25-038301.json","markdown":"https://secwatch.observer/filing/0001104659-25-038301.md","text":"https://secwatch.observer/filing/0001104659-25-038301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/0001104659-25-038301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:26:40.292508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}